Abbott blood screening
This article was originally published in The Gray Sheet
Executive Summary
Abbott announces biologics license approval Jan. 18 for a fully automated blood screening test for antibodies to human T-lymphotropic virus Types I and II on the firm's Prism system. The HTLV-I and II retroviruses are associated with leukemia and neurological disorders, among other diseases, and are screened for in all U.S. blood donations. Abbott says the new test offers an alternative to its HTLV-I/II assay approved in 1997 that runs on the semi-automated Commander system. Prism, which launched in the U.S. in 2005, also runs four tests for hepatitis